Nuclear receptors are ligand-inducible transcriptional factors, and regulate various signiˆcant biological phenomena such as cell diŠerentiation, proliferation, metabolism, and homeostasis. By the elucidation of the physiological functions of nuclear receptors, they have become one of the most signiˆcant molecular targets for drug discovery in theˆelds of cancer, autoimmune diseases, and metabolic syndrome. In this study, several novel nuclear receptor ligands have been developed, based on the receptor-folding inhibition hypothesis is discussed. In this hypothesis, the antagonists for nuclear receptors are classiˆed into two types, the misfolding inducers and the folding inhibitors, related to the helix 12 (AF-2 region) conformation of the receptor that is signiˆcant for the receptor activation. Then, in order to overcome the resistance in the treatment of prostate tumors with androgen antagonists, the novel folding-inhibitor type antagonists such as isoxazole and pyrrolecarboxamide derivatives were designed and synthesized. Some of them exhibited the androgen antagonistic activities in LNCaP cells with mutated androgen receptor in which conventional antagonists such as ‰utamide and RU56187 were inactive. The folding-inhibitor type vitamin D 3 antagonists (DLAM series) are similarly developed. Further, novel non-seco-steroidal vitamin D 3 analogs were designed and synthesized by using a 3,3-diphenylpropane derivative, LG190178 as lead compound. The aza analogs exhibited both potent vitamin D agonistic and androgen antagonistic activities. The results indicate the drug design based on the receptor-folding inhibition hypothesis is e‹cient in medicinal chemistry of nuclear receptors.
. Structure-activity of Pyrrolecarboxamides 1 and 2 Table 1 a) The chiralities are described as (chiral-1, chiral-2). 
